Completed NA INTERVENTIONAL 1-arm NCT00544219

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

Sponsor: Swiss Cancer Institute

Conditions Lymphoma

Interventions cyclophosphamide doxorubicin hydrochloride positron emission tomography prednisone rituximab vincristine sulfate

Updated 8 times since 2017 Last updated: May 13, 2019 Started: Sep 30, 2007 Primary completion: Sep 30, 2012 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Lymphoma, this trial is completed. The trial is conducted by Swiss Cancer Institute and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Aug 2025 — Sep 2025 [monthly]

Completed NA
Sep 2024 — Aug 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Jun 2019 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Cancer Institute

Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Baden, Switzerland , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Bruderholz, Switzerland , Chur, Switzerland , Geneva, Switzerland , Liestal, Switzerland , Milan, Italy and 6 more locations